Table 3 Hazard ratios of pre- and post-menopausal breast cancer according to acrylamide intake for women who have never smoked
From: Dietary acrylamide intake and risk of breast cancer in the UK women's cohort
Model 1 a | Model 2 b | |||||||
|---|---|---|---|---|---|---|---|---|
Fifth of acrylamide intake | Range ( μ g day−1) | Cases/Total | HR | 95% CI | P trend c | HR | 95% CI | P trend c |
All breast cancers | ||||||||
1 | 0–9 | 128/3584 | 1.00 | — | 1.00 | — | ||
2 | 9–13 | 114/3745 | 0.78 | (0.60, 1.03) | 0.87 | (0.63, 1.20) | ||
3 | 13–17 | 130/3847 | 0.82 | (0.63, 1.07) | 0.95 | (0.69, 1.30) | ||
4 | 17–23 | 120/3885 | 0.79 | (0.60, 1.03) | 0.96 | (0.69, 1.34) | ||
5 | 23–150 | 115/3841 | 0.82 | (0.62, 1.07) | 0.98 | (0.69, 1.40) | ||
Trend (per 10 μg day−1) | 0.94 | (0.85, 1.04) | 0.2 | 1.06 | (0.93, 1.21) | 0.4 | ||
Premenopausal | ||||||||
1 | 0–9 | 45/1604 | 1.00 | — | 1.00 | — | ||
2 | 9–13 | 38/1709 | 0.73 | (0.45, 1.19) | 0.68 | (0.39, 1.20) | ||
3 | 13–17 | 59/1805 | 1.04 | (0.68, 1.61) | 1.12 | (0.69, 1.83) | ||
4 | 17–23 | 54/1990 | 0.80 | (0.51, 1.25) | 0.98 | (0.59, 1.62) | ||
5 | 23–150 | 57/2024 | 1.00 | (0.65, 1.54) | 1.17 | (0.69, 2.00) | ||
Trend (per 10 μg day−1) | 1.01 | (0.88, 1.15) | 0.9 | 1.13 | (0.95, 1.33) | 0.2 | ||
Postmenopausal | ||||||||
1 | 0–9 | 76/1972 | 1.00 | — | 1.00 | — | ||
2 | 9–13 | 76/2036 | 0.89 | (0.64, 1.26) | 0.98 | (0.66, 1.46) | ||
3 | 13–17 | 71/2042 | 0.79 | (0.56, 1.13) | 0.83 | (0.54, 1.26) | ||
4 | 17–23 | 66/1895 | 0.89 | (0.63, 1.25) | 0.99 | (0.64, 1.53) | ||
5 | 23–150 | 58/1817 | 0.81 | (0.57, 1.16) | 0.86 | (0.53, 1.37) | ||
Trend (per 10 μg day−1) | 0.95 | (0.83, 1.08) | 0.4 | 1.01 | (0.83, 1.24) | 0.9 | ||
